Welcome to our dedicated page for CELLBXHEALTH PLC news (Ticker: ANPCY), a resource for investors and traders seeking the latest updates and insights on CELLBXHEALTH PLC stock.
Angle Plc (ANPCY) provides cutting-edge liquid biopsy solutions for cancer diagnostics and research. This news hub delivers official updates on clinical trial progress, regulatory milestones, and strategic partnerships shaping precision oncology.
Access verified announcements about the Parsortix system deployments, novel assay developments, and collaborations with pharmaceutical leaders. Investors and researchers will find timely reports on FDA submissions, peer-reviewed study publications, and innovations in circulating tumor cell (CTC) analysis.
Key updates include product launch details, intellectual property expansions, and clinical service offerings supporting drug development. All content undergoes strict verification to ensure accuracy in reporting financial and operational developments.
Bookmark this page for consolidated access to Angle Plc's latest advancements in non-invasive cancer diagnostics and genomic analysis technologies.
Angle PLC announced a study using their Parsortix system to analyze circulating tumor cells (CTCs) from 123 metastatic ovarian cancer patients over two and a half years. The study, the largest of its kind, involved 474 blood samples and identified two key gene markers: ERCC1, linked to worse outcomes, and ESR1, linked to better outcomes. The presence of ESR1 and absence of ERCC1 in CTCs correlated with improved progression-free survival (PFS). This research suggests that molecular characterization of CTCs could be valuable for monitoring ovarian cancer and predicting treatment responses in clinical trials.
ANGLE plc has announced a new commercial agreement with AstraZeneca to develop a Parsortix-based Androgen Receptor detection assay for prostate cancer studies, worth £550,000. The assay is expected to be completed by Q1 2025 and could provide significant revenue opportunities for the company. The Parsortix system will allow for minimally invasive assessment of the Androgen Receptor status, important in prostate cancer treatment. This agreement further validates ANGLE's technology and potential for long-term revenue growth.
FAQ
What is the current stock price of CELLBXHEALTH PLC (ANPCY)?
What is the market cap of CELLBXHEALTH PLC (ANPCY)?
